至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Preamplification-free ultra-fast and ultra-sensitive point-of-care testing via LwaCas13a

Biosens Bioelectron. 2024-05; 
Wanting Zeng, Wanping Chen, Yang Liu, Ting Zhang, Chao Zhai, Wenqiang Li, Longyu Wang, Cheng Zhang, Qili Zeng, Fei Wang, Lixin Ma
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis … The RNA used in this research were purchased from the GenScript Biotech Corporation (… et al., 2020), and three targets from the Nucleocapsid protein (N) gene fragment were selected … Get A Quote

摘要

CRISPR based nucleic acid detection technology provides a deployable approach to point of care testing. While, there remain challenges limiting its practical applications, such as the need for pre-amplification and the long turnaround time. Here, we present a self-cascade signal amplification method with LwaCas13a and an artificially designed "U" rich RNA of stem-loop structure (URH) for pre-amplification-free ultra-fast and ultra-sensitive point-of-care testing (PASSPORT). The PASSPORT system contains: URH, crRNA targeted the URH, crRNA targeted the interesting RNA, fluorescent RNA reporter and LwaCas13a. The assay realized the detection of 100 copies/mL, within 5 min. The PASSPORT platform was further adopte... More

关键词

CRISPR/Cas13a, Lateral flow, Point-of-care testing, Preamplification-free, SARS-CoV-2